# Molecular Partners AG: overview MOLN · Nasdaq · CIK 1745114 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/moln.md) · [Financials](/companies/moln/financials.md) · [Filings](/companies/moln/filings.md) · [Insiders](/companies/moln/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [9.8](/filings/0001745114-24-000003.md) | [190](/filings/0001745114-25-000009.md) | [7.0](/filings/0001745114-25-000009.md) | [5.0](/filings/0001745114-25-000009.md) | [0.0](/filings/0001745114-26-000009.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(650.2%)](/filings/0001745114-24-000003.md) | [61.5%](/filings/0001745114-25-000009.md) | [(868.3%)](/filings/0001745114-26-000009.md) | [(1231.7%)](/filings/0001745114-26-000009.md) | not reported | | Net margin | % | [(653.9%)](/filings/0001745114-24-000003.md) | [62.2%](/filings/0001745114-25-000009.md) | [(880.7%)](/filings/0001745114-26-000009.md) | [(1087.4%)](/filings/0001745114-26-000009.md) | not reported | | Diluted EPS | $ per share | [(2.06)](/filings/0001745114-24-000003.md) | [3.54](/filings/0001745114-25-000009.md) | [(1.89)](/filings/0001745114-26-000009.md) | [(1.59)](/filings/0001745114-26-000009.md) | [(1.65)](/filings/0001745114-26-000009.md) | | Free cash flow | $m | [(91.9)](/filings/0001745114-24-000003.md) | [117](/filings/0001745114-25-000009.md) | [(59.6)](/filings/0001745114-26-000009.md) | [(60.0)](/filings/0001745114-26-000009.md) | [(52.0)](/filings/0001745114-26-000009.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue; Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue; Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue; Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:Revenue; Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/moln/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $8.6m | 2,221,494 | | Unchanged | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $5.1m | 1,353,968 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $65.3k | 17,179 | | New +17,179 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.4k | 367 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $1.1k | 279 | | New +279 | ## Recent filings [All 120 filings](/companies/moln/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 06:04 ET | [6-K](/filings/0001745114-26-000033.md) | Report of a foreign private issuer, period 2026-09-30 | 0001745114-26-000033 | | 2026-08-25 | 06:03 ET | [6-K](/filings/0001745114-26-000028.md) | Report of a foreign private issuer, period 2026-06-30 | 0001745114-26-000028 | | 2026-07-20 | 08:22 ET | [6-K](/filings/0001171843-26-004758.md) | Report of a foreign private issuer, period 2026-07-16 | 0001171843-26-004758 | | 2026-07-07 | 18:00 ET | [6-K](/filings/0001171843-26-004488.md) | Report of a foreign private issuer, period 2026-07-06 | 0001171843-26-004488 | | 2026-07-02 | 06:00 ET | [6-K](/filings/0001171843-26-004433.md) | Report of a foreign private issuer, period 2026-07-02 | 0001171843-26-004433 | | 2026-06-01 | 07:18 ET | [6-K](/filings/0001171843-26-003818.md) | Report of a foreign private issuer, period 2026-05-30 | 0001171843-26-003818 | | 2026-05-12 | 16:01 ET | [6-K](/filings/0001745114-26-000019.md) | Report of a foreign private issuer, period 2026-03-31 | 0001745114-26-000019 | | 2026-05-01 | 09:21 ET | [6-K](/filings/0001171843-26-002920.md) | Report of a foreign private issuer, period 2026-05-01 | 0001171843-26-002920 | | 2026-04-14 | 16:44 ET | [6-K](/filings/0001171843-26-002441.md) | Report of a foreign private issuer, period 2026-04-14 | 0001171843-26-002441 | | 2026-03-30 | 07:06 ET | [6-K](/filings/0001745114-26-000015.md) | Report of a foreign private issuer, period 2026-03-31 | 0001745114-26-000015 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001745114-26-000009.md), filed Mar 12, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1745114 - Tickers: MOLN - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: V8 - Filer category: Non-accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 06:05 ET. No prices; not investment advice.